Viyash Scientific Limited will host Viyash Investor Day - 2026 on June 25, 2026, in Mumbai. The meeting is intended for analysts and institutional investors and will be conducted in physical mode. The company stated that the schedule may change due to exigencies on the part of investors, analysts, or the company.

The investor presentation will be made available on the BSE Limited and National Stock Exchange of India Limited before the event. It will also be accessible on the company's website at www.viyash.com . Viyash Scientific clarified that it will refer only to publicly available information during the discussions and no unpublished price sensitive information will be shared.

Event Schedule

The intimation was submitted to the exchanges pursuant to Regulation 30 read with Para A of Part A of the Schedule III of the SEBI Listing Regulations. Yoshita Vora, Company Secretary & Compliance Officer, signed the disclosure on June 17, 2026.

Viyash Scientific Limited has signed a binding agreement to acquire 100% stake in BioForLife Italia S.r.l. for an aggregate consideration of EUR 16.975 million, strengthening its presence in the European companion animal health market. The transaction, executed through its step-down wholly owned subsidiary Alivira Animal Health Limited, is expected to close within three months from the execution of the agreement, subject to fulfilment of conditions precedent and regulatory approvals. This strategic move aims to capitalize on the growing Companion Animal Health Generics market and establish a platform in Italy, which ranks among the five largest animal health markets in Europe.

Acquisition Details

The following table summarises the key parameters of the transaction:

Financial Structure and Approvals

The aggregate consideration of EUR 16.975 million is structured as EUR 15.0 million payable at closing and EUR 1.975 million as deferred consideration. The transaction is subject to fulfilment of applicable conditions precedent and receipt of statutory and regulatory approvals, including notification under Italian Golden Power Laws (Decree-Law No. 21/2012). The deferred consideration is expected to be settled within 12 months from closing or earlier upon the occurrence of the relevant trigger.

Strategic Rationale and Operations

BioForLife specializes in the development, commercialization, and distribution of products for veterinary use, including medicines, nutraceuticals, and testing kits. The company reaches over 80% of all veterinary clinics in Italy. Reported annual sales for CY 2025 were approximately EUR 9.0 million. The acquisition is intended to strengthen and scale Viyash Scientific's presence in Italy in the companion animal segment through an established front-end platform, customer reach, and product capabilities. The deal also facilitates the launch of new products from Alivira's pipeline in Italy and the expansion of the BioForLife range to other markets in Europe, the Middle East, Asia, and Latam.